ClinicalTrials.gg
TerminatedNCT03322371Updated Jun 8, 2021

Validation of Frontal EEG to Formal Polysomnography in the ICU

An interventional study of 2-lead limited electroencephalography recording in Sleep Deprivation and Sleep, sponsored by University of Utah. Terminated at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by University of Utah · Not applicable, Interventional, and Diagnostic

Why this study was terminated
Difficulty analyzing PSG data
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 146 studies in Sleep Deprivation with a site in United States — 30 open to participants now, 35 under way, none of them phase 3. Sleep Deprivation · United States.

Enrollment
71st of 127
44 · median 56
Started
2017
with 8 others
No phase
104 of 146
25 open now
Registered
64th of 146
by date
Lead sponsor
5 of 146
University of Utah

Among the 146 studies in Sleep Deprivation with a site in United States, this one is the 71st largest by enrollment of the 127 interventional ones that give a count, is one of 9 that started in 2017, is one of 104 with no phase, and was the 64th registered.

Sleep Deprivation

314 studies on the registry are indexed under Sleep Deprivation; 59 are open to participants now.

Browse Sleep Deprivation studies →

Open to participants now

30 of the 146 studies in Sleep Deprivation with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Sleep Deprivation studies recruiting now, 11 (26%) set no upper age limit and 28 (65%) stop at 75 or younger; 5 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Sleep Deprivation with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare a 2-lead frontal electroencephalogram recording to a formal polysomnography (PSG) in detecting sleep vs. wake and depth of sleep in both healthy and ICU patients.

Read the detailed description

Sleep in the intensive care unit (ICU) is poor and not well understood. Formal polysomnography (PSG) is the gold standard measure, but impractical for critical care. The relative influence of environment, illness and interventions on sleep in critically ill patients is therefore essentially unknown. Interventions to improve sleep have been pragmatic and outcomes subjective or indirect, and uninformed. When it is done, formal PSG in critical illness demonstrates fragmented, shortened, interrupted and non-circadian sleep, with environmental noise, light, and frequent physical stimulation causing arousals.

03

Conditions studied

  • Sleep Deprivation
  • Sleep

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Group 1: Healthy Subjects in Sleep Lab:

Inclusion Criteria

  • Age 18 or older
  • Scheduled for a standard of care polysomnography lasting at least 8 hours for any condition

Exclusion Criteria

  • Patient/Legally Authorized Representative declines consent

Group 2: ICU patient, not sedated, not ventilated

Inclusion Criteria

  • Age 18 or older
  • Anticipated to stay in intensive care unit overnight (minimum 8 hours)
  • Glasgow Coma Scale score of 13 or great

Exclusion Criteria:

  • Intubated with endotracheal tube
  • Sedated (includes sedative drugs such as propofol, Dexmedetomidine, versed infusion above 2mg/hr, ketamine infusion above 0.2 mg/kg/hr).

Group 3: ICU patient, sedated and ventilated

Inclusion Criteria:

  • Age 18 or older
  • Anticipated to stay in the intensive care unit overnight (minimum 8 hours)
  • Intubated, sedated, and ventilated

Exclusion Criteria:

  • Presence of traumatic brain injury
  • Planned extubation in next 8 hours
  • Scheduled to leave the intensive care unit for any reason in the next 8 hours
  • Anticipated of less than 24 hours
  • Electroencephalogram monitoring (current or scheduled in the next 8 hours)
  • Hemodynamic instability (defined as: (i) mean arterial pressure \<60mmHg for >20 minutes with efforts to raise it or (ii) >2 liter fluid administered in 2h after operating room and anticipating on-going needs for fluid resuscitation or (iii) ICU MD determination of "atypical and profound hemodynamic instability" or (iv) PI determination after evaluation.
  • hypoxemia - defined as Saturation \<88% on Sp02 despite efforts to increase it
  • Hemorrhage - defined as >500cc chest tube output in 2h and anticipated need of more than 2 units of packed red blood cells in immediate post op period. This does NOT include cell-saver.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Other
    Health Subjects in Sleep Lab

    Adult patients (\> 18yrs old) scheduled for a standard of care PSG (sleep study) lasting at least 8 hours for any condition. Patients will undergo simultaneous 2-lead limited EEG recording with experimental device. 2-lead limited electroencephalography recording

    Device: 2-lead limited electroencephalography recording

  • Other
    ICU patients, not sedated or ventilated

    Adult ICU patients (\> 18yrs old) anticipated to stay in the ICU overnight (minimum 8 hours) with a Glasgow Coma Scale of 13 or greater, not intubated and not sedated. Patients will undergo simultaneous 2-lead limited electroencephalography recording

    Device: 2-lead limited electroencephalography recording

  • Other
    ICU patients, sedated and ventilated

    Adult ICU patients (\> 18yrs old) who are intubated, sedated, ventilated, and anticipated to stay in the ICU overnight (minimum 8 hours). Patients will undergo simultaneous 2-lead limited electroencephalography recording

    Device: 2-lead limited electroencephalography recording

Interventions

  • Device2-lead limited electroencephalography recording

    The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.

    Also known as: Health Subjects in Sleep Lab, ICU patients, not sedated or ventilated, ICU patient, sedated and ventilated

06

What researchers measure

Primary outcomes

  1. Sleep Stage Correlation

    The correlation of each sleep stage (Wake, NREM1, NREM2, NREM3, REM) as assessed by polysomnography vs. EEG via analysis of 30-second intervals (epochs)

    Time frame: Overnight (with a minimum of 960 epochs)

Secondary outcomes

  1. Sleep vs Wake Correlation

    The correlation of sleep (NREM1, NREM2, NREM3, REM) vs wake as assessed by polysomnography vs. EEG via analysis of 30-second intervals (epochs)

    Time frame: Overnight (with a minimum of 960 epochs)

Other outcomes

  1. Sound and Light during Sleep

    The correlation of sleep stage (Wake, NREM1, NREM2, NREM3, REM) with sound and light levels within the ICU.

    Time frame: Overnight (with a minimum of 960 epochs)

  2. Environmental Conditions during Sleep

    The correlation of sleep stage (Wake, NREM1, NREM2, NREM3, REM) with environmental conditions within the ICU.

    Time frame: Overnight (with a minimum of 960 epochs)

07

Study locations

1 site
  • University of Utah
    Salt Lake City, Utah 84132, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Jan 2020, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2017
First posted
Oct 26, 2017
StartActual
Nov 6, 2017
Primary completionActual
Jan 1, 2020
CompletionActual
Jan 1, 2020
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03322371
Lead sponsor
University of Utah
Collaborators
Epitel, Inc.
Responsible party
Joseph Tonna (Associate Director, ECMO Services, University of Utah) — Principal investigator
First posted
Oct 26, 2017
Start date
Nov 6, 2017
Primary completion
Jan 1, 2020
Completion
Jan 1, 2020
Last update
Jun 8, 2021

Study contacts

Joseph Tonna, MD, FAAEM
principal investigator · University of Utah

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion